EpiGenesis Pharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

EpiGenesis Pharmaceuticals General Information

Description

Developer of inhaled respiratory medicines created to improve the health and quality of life in patients with respiratory diseases. The Company's current lead compound, EPI-12323, is a once daily inhaled non-glucocorticoid steroid that targets the inflammatory and airway obstruction cascade in the irritated lung and treats asthma and chronic obstructive pulmonary disease (COPD).

Contact Information

Website
www.epigene.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Clarke Drive
  • Cranbury, NJ 08512
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 7 Clarke Drive
  • Cranbury, NJ 08512
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EpiGenesis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Jan-2012 Completed Out of Business
4. Early Stage VC (Series B) 29-Jun-2007 Completed Generating Revenue
3. Early Stage VC (Series A) 09-Jun-2003 Completed Startup
2. Seed Round 01-Feb-1998 $2.5M $2.5M Completed Startup
1. Grant 21-Oct-1997 $100K Completed Startup
To view EpiGenesis Pharmaceuticals’s complete valuation and funding history, request access »

EpiGenesis Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view EpiGenesis Pharmaceuticals’s complete cap table history, request access »

EpiGenesis Pharmaceuticals Patents

EpiGenesis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2008296195-A1 (dheas) inhalation compositions Inactive 07-Sep-2007
CA-2698683-A1 Dheas inhalation compositions Inactive 07-Sep-2007
EP-2197452-A1 Dheas inhalation compositions Inactive 07-Sep-2007
EP-2197452-A4 Dheas inhalation compositions Inactive 07-Sep-2007
US-20090118249-A1 Dheas inhalation compositions Inactive 07-Sep-2007 A61K31/704
To view EpiGenesis Pharmaceuticals’s complete patent history, request access »

EpiGenesis Pharmaceuticals FAQs

  • When was EpiGenesis Pharmaceuticals founded?

    EpiGenesis Pharmaceuticals was founded in 1995.

  • Where is EpiGenesis Pharmaceuticals headquartered?

    EpiGenesis Pharmaceuticals is headquartered in Cranbury, NJ.

  • What industry is EpiGenesis Pharmaceuticals in?

    EpiGenesis Pharmaceuticals’s primary industry is Drug Delivery.

  • Is EpiGenesis Pharmaceuticals a private or public company?

    EpiGenesis Pharmaceuticals is a Private company.

  • What is EpiGenesis Pharmaceuticals’s current revenue?

    The current revenue for EpiGenesis Pharmaceuticals is .

  • How much funding has EpiGenesis Pharmaceuticals raised over time?

    EpiGenesis Pharmaceuticals has raised $39.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process